SavedAdd your journal

Journals / Türk Biyokimya Dergisi / 2020 / Cilt: 45 - Sayı: 2

Effects of topiramate on adipocyte differentiation and gene expression of certain carbonic anhydrase isoenzymes

Topiramatın adiposit farklılaşması ve bazı karbonikanhidraz izoenzimleri gen ekspresyonu üzerineetkileri

Ayşegül SÜMER
Ahmet MENTEŞE
Eşref Edip KEHA
Ahmet ALVER
Pages
12–20
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: It was found that topiramate induced adipogenesis at all concentrations (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Topiramate, an antiepileptic drug, besides its known effects in neurons, is a carbonic anhydrase inhibitor and causes weight loss in treated subjects, but, the mechanisms of weight loss effect have not been yet identified..
📊
Key Findings & Data:Objective: In this study, effects of topiramate on 3T3-L1 adipocyte differentiation and expressions of carbonic anhydrase I, II, III, VA, VB were investigated to determine possible roles of carbonic anhydrase isoenzymes and adipocytes in weight loss effect of topiramate.
💡
Conclusion & Impact:Results: It was found that topiramate induced adipogenesis at all concentrations (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: Topiramate, an antiepileptic drug, besides its known effects in neurons, is a carbonic anhydrase inhibitor and causes weight loss in treated subjects, but, the mechanisms of weight loss effect have not been yet identified.. Objective: In this study, effects of topiramate on 3T3-L1 adipocyte differentiation and expressions of carbonic anhydrase I, II, III, VA, VB were investigated to determine possible roles of carbonic anhydrase isoenzymes and adipocytes in weight loss effect of topiramate. Material and methods: Adipocyte differentiation was detected by Oil Red O staining. Carbonic anhydrase I, II, III, VA, VB expressions were determined by Real-Time PCR method. Results: It was found that topiramate induced adipogenesis at all concentrations (p

Özet

Genel Bilgiler: Antiepileptik bir ilaç olan topiramat, nöronlardaki bilinen etkilerinin yanı sıra, karbonik anhidraz inhibitörü olup tedavi alan kişilerde kilo kaybına neden olmaktadır, ancak ilgili mekanizmalar henüz aydınlatılamamıştır. Amaç: Bu çalışmada, topiramatın 3T3-L1 adiposit farklılaşması üzerindeki etkileri ve karbonik anhidraz I, II, III, VA, VB ekspresyonları incelenerek bu izoenzimlerin ve adipositlerin, topiramatın kilo kaybı etkisindeki olası rollerini belirlemek amaçlanmıştır. Gereç ve Yöntemler: Adiposit farklılaşması Oil red O boyaması ile saptanırken, karbonik anhidraz I, II, III, VA, VB’nin ekspresyonları real-time PCR tekniği ile belirlendi. Bulgular: Topiramat tüm konsantrasyonlarda adipogenezi artırdığı bulunmuştur (p

🔖

Cite This Article

SÜMER, A., MENTEŞE, A., KEHA, E. E., ALVER, A. (2022). Effects of topiramate on adipocyte differentiation and gene expression of certain carbonic anhydrase isoenzymes. Türk Biyokimya Dergisi, Cilt: 45 - Sayı: 2, 12–20. https://ajindex.com/articles/620764

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Khan Md Y, Gubta P, Bihari B, Misra A, Pathak A, Verma VK. A review on obesity and its management. Intl J Sci Eng Res 2012;3:11
  2. Bays HE. Current and investigational antiobesity agents and obesity treatment targets. Obes Res 2004;12:1197–211
  3. Dias S, Paredes S, Ribeiro L. Drugs involved in dyslipidemia and obesity treatment: focus on adipose tissue. Int J Endocrinol 2018:2637418
  4. Shin JH, Gadde KM. Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity. Diabetes Metab Syndr Obes 2013;6:131–9
  5. Supuran CT. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs 2012;17:11–5
  6. Frost SC, McKenna R. Carbonic anhydrase: mechanism, regulation, link to disease, and industrial applications. Dordrecht Heidelberg New York London: Springer, 2014;9:291–325
  7. Novakofski J. Adipogenesis: usefulness of in vitro and in vivo experimental models. J Anim Sci 2004;82:905–15
  8. Supuran CT. Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity. Expert Opin Ther Patents 2003;13:1545–50
  9. Ramirez-Zacarias JL, Castro-Munozledo F, Kuri-Harcuch W. Quantitation of adipose conversion and triglycerides by staining intracytoplasmic lipids with Oil Red O. Histochemistry 1992;97:493–7 10. Pan PW, Rodriguez A, Parkkila S. A systematic quantification of carbonic anhydrase transcripts in the mouse digestive system. BMC Mol Biol 2007;8:22
  10. Supuran CT, Winum JY. Drug design of zinc enzymes. New Jersey: John, Wiley & Sons, 2009:241–51
  11. Gensel JC, Tovar CA, Bresnahan JC, Beattie MS. Topiramate treatment is neuroprotective and reduces oligodendrocyte loss after cervical spinal cord injury. PLoS One 2003;7:e33519
  12. York DA, Singer L, Thomas S, Bray GA. Effect of topiramate on body weight and body composition of Osborne-Mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs. Nutrition 2000;16:967–75
  13. Moradi S, Kerman SR, Mollabashi M. The effect of topiramate on weight loss in patients with type 2 diabetes. J Res Med Sci 2013;18:297–302
  14. Verrotti A, Scaparrotta A, Agostinelli S, Di Pillo S, Chiarelli F, Grosso S. Topiramate-induced weight loss: a review. Epilepsy Res 2011;95:189–99
  15. Martins GP, Souza CO, Marques SD, Luciano TF, Pieri BL, Rosa JC, et al. Topiramate effects lipolysis in 3T3-L1 adipocytes. Bıomed Rep 2015;3:827–30
  16. Angehagen M, Ben-Menachem E, Rönnbäck L, Hansson E. Topiramate protects aga